AlphaQuest LLC Sells 12,031 Shares of DaVita Inc. $DVA

AlphaQuest LLC reduced its position in shares of DaVita Inc. (NYSE:DVA) by 92.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 945 shares of the company’s stock after selling 12,031 shares during the quarter. AlphaQuest LLC’s holdings in DaVita were worth $126,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in DVA. NewEdge Advisors LLC raised its stake in shares of DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after buying an additional 88 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of DaVita by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after acquiring an additional 28,739 shares during the last quarter. Aberdeen Group plc lifted its stake in shares of DaVita by 16.5% in the 2nd quarter. Aberdeen Group plc now owns 49,209 shares of the company’s stock valued at $7,010,000 after purchasing an additional 6,956 shares during the period. Vanguard Personalized Indexing Management LLC boosted its position in shares of DaVita by 13.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,214 shares of the company’s stock worth $885,000 after purchasing an additional 713 shares during the last quarter. Finally, Sequoia Financial Advisors LLC grew its stake in shares of DaVita by 7.6% during the second quarter. Sequoia Financial Advisors LLC now owns 2,018 shares of the company’s stock worth $287,000 after purchasing an additional 143 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on DVA shares. Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Truist Financial set a $158.00 price objective on shares of DaVita in a research note on Thursday, February 5th. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. Barclays increased their target price on shares of DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. Finally, TD Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $160.50.

DaVita Stock Performance

Shares of NYSE DVA opened at $149.84 on Friday. The stock has a 50 day moving average price of $117.07 and a 200 day moving average price of $125.00. The stock has a market capitalization of $10.58 billion, a PE ratio of 15.12, a price-to-earnings-growth ratio of 0.50 and a beta of 0.99. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $178.38.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, topping the consensus estimate of $3.24 by $0.16. The firm had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, research analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.